Evidence map›Paper›PMID 42873849›Full record

Trial reportScience advances2026

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer.

Apostolia M Tsimberidou, Christopher R Cabanski, Alexandra Drakaki, Danny N Khalil, Bilal A Siddiqui, Sreyashi Basu, Kwame Okrah, Diane M Da Silva, Shikha Gautam, Farah A Alayli and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03651271 (An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03651271 phase2completednot on this map

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

TypeinterventionalSponsorParker Institute for Cancer ImmunotherapyRan2018 to 2023Enrolled100ConditionsAdvanced Metastatic Cancer, Advanced Prostate CancerArmsNivolumab Monotherapy, Nivolumab and Ipilimumab and Combination for Metastatic Cancer, Nivolumab and Ipilimumab (3 mg/kg) Combination for Prostate Cancer, Nivolumab and Ipilimumab (5 mg/kg) Combination for Prostate Cancer
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Apostolia M TsimberidouDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher R CabanskiParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0009-0007-9938-1331
Alexandra DrakakiUniversity of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.ORCID 0000-0001-8865-3548
Danny N KhalilDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4688-0958
Bilal A SiddiquiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6806-1294
Sreyashi BasuJames P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5028-3833
Kwame OkrahParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Diane M Da SilvaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0000-0001-7317-4886
Shikha GautamParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0000-0003-4885-7823
Farah A AlayliParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0009-0003-1155-1756
Mike SchachterParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Justin FairchildParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0000-0002-4478-7146
Wai Chin FooDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-0471-4911
Silvia BoffoBristol Myers Squibb, New York, NY, USA.ORCID 0000-0002-6352-160X
Jamie ArnottParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID 0009-0009-6073-6259
Ute DuganParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5208-7732
Padmanee SharmaDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4658-055X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint therapies have shown limited efficacy in metastatic castration-resistant prostate cancer (mCRPC). The AMADEUS prostate expansion cohort (NCT03651271) evaluated the efficacy, safety, and biomarkers of escalating ipilimumab doses combined with nivolumab. Patients received ipilimumab 1 milligram per kilogram (mg/kg) + nivolumab 360 mg (I1+N360), ipilimumab 3 mg/kg + nivolumab 1 mg/kg (I3+N1), or ipilimumab 5 mg/kg + nivolumab 1 mg/kg (I5+N1). Coprimary endpoints were 6-month disease control rate (DCR) and changes in tumoral CD8 percentage. Thirty-two patients were enrolled. DCRs were 33% (4 of 12) for I1+N360, 20% (1 of 5) for I3+N1, and 20% (3 of 15) for I5+N1. Across cohorts, tumoral CD8 percentage increased by a median of 5.0%. Although higher ipilimumab doses were tolerable, I1+N360 achieved similar disease control and immune activation with a more favorable safety profile. Early disease progression was associated with increased expression of a TREM2-associated myeloid gene signature, which was also significantly enriched in two independent prostate cancer datasets.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDrug Resistance, NeoplasmIpilimumabNivolumabProstatic Neoplasms, Castration-ResistantAgedHumansMaleMiddle AgedNeoplasm MetastasisTreatment OutcomeBiomarkers, TumorIpilimumabNivolumab

Identifiers

PMID42873849
PMCPMC13666023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.